PDCD1 and neoplasm: R-123, a modified version of R-115 (see 5.2) that expresses both IL-12 and GM-CSF, inhibited HER2-LLC tumor growth, with about 40% of responders, which was improved to 100% cures when combined with anti-PD-1 [171].